Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26101871 | 1.00 | USP30 (0.47) | USP30GPR119JAK2JAK1ALDH1A1 | |
| SCHEMBL26101492 | 0.84 | GPR119 (0.50) | GPR119JAK2JAK1 | |
| SCHEMBL26101487 | 0.84 | GPR119 (0.50) | GPR119JAK2JAK1 | |
| SCHEMBL19297555 | 0.80 | GPR119 (0.55) | USP30GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL247897 | 0.78 | MAPT (0.59) | USP30GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL3375291 | 0.77 | USP30 (0.53) | USP30GPR119LMNAMAPT | |
| SCHEMBL19297521 | 0.77 | USP30 (0.54) | USP30GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL16625316 | 0.77 | USP30 (0.57) | USP30GPR119 | |
| SCHEMBL27391745 | 0.77 | USP30 (0.52) | USP30GPR119 | |
| SCHEMBL26099504 | 0.77 | USP30 (0.33) | USP30ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | USP30 574/4885GPR119 3223/4885JAK2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.